June 13, 2005 After trading higher for most of the day, biotech sold off during the final hour of the session, kicking off the new week with a small loss. At the close, the Centient Biotech 200 was 5 points lower at 3330.14, a slide of .13%. Connectics got clobbered after receiving a not-approvable letter for its acne drug, Pfizer added an epilepsy indication to Lyrica, Sanofi-Aventis won approval for a non-pediatric whooping cough vaccine, Exelixis raised as much as $80 million in a deal with a very unusual structure, Renovis will end development of an MS drug, Theravance said its bronchodilator has entered trials, Genta reported clinical success for Genasense, and Cell Therapeutics sold a leukemia drug to Cephalon. More details...
